Once-a-day weight loss pill saw obese people shed 13% of body weight in three months

Novo Nordisk's phase one trial included adults without diabetes, who had a body mass index (BMI) of between 25 and 39.9, a range considered overweight to obese.

A new weight loss pill developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% of their body weight in three months, an early trial has found.

However, experts say that while pills may be cheaper when compared to injectable drugs like semaglutide — of which there is a shortage — more research is needed.